Alnylam Pharmaceuticals Inc
NASDAQ:ALNY

Watchlist Manager
Alnylam Pharmaceuticals Inc Logo
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Watchlist
Price: 456.44 USD -1.91% Market Closed
Market Cap: 60.3B USD
Section:
 

Relative Value

The Relative Value of one ALNY stock under the Base Case scenario is hidden USD. Compared to the current market price of 456.44 USD, Alnylam Pharmaceuticals Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ALNY Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

24.3
P/S
P/S
Price to Sales
24.3
vs History
31
vs Industry
34
Median 3Y
16.9
Median 5Y
21.4
Industry
7.9
Forward
16.1
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-58.4
Median 5Y
-26
Industry
24
Forward
310.8
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
1
Median 3Y
-46.9
Median 5Y
-34.1
Industry
21.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
0
Median 3Y
-93.6
Median 5Y
-58.2
Industry
23.7
More Details
238.6
P/B
P/B
Price to Book Value
238.6
vs History
14
vs Industry
0
Median 3Y
-85.6
Median 5Y
18.3
Industry
3.4
More Details
23.5
EV/S
EV/S
Enterprise Value to Sales
23.5
vs History
30
vs Industry
29
Median 3Y
16.1
Median 5Y
20.6
Industry
8.3
Forward
15.6
More Details
28.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
28.1
vs History
31
vs Industry
27
Median 3Y
18.9
Median 5Y
24.7
Industry
10.3
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-99.3
Median 5Y
-31.2
Industry
6.7
Forward
119.9
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-80.3
Median 5Y
-29.6
Industry
7.2
Forward
166.7
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
1
Median 3Y
-44.8
Median 5Y
-31.6
Industry
8.2
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
1
Median 3Y
-42
Median 5Y
-30.2
Industry
6.7
More Details
36.1
EV/IC
EV/IC
Enterprise Value to IC
36.1
vs History
0
vs Industry
10
Median 3Y
21
Median 5Y
17.8
Industry
5.7
More Details

Multiples Across Competitors

ALNY Competitors Multiples
Alnylam Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
59.8B USD 24.3 -187.4 -468.5 -321.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 059 881.3 -161 881.6 -196 575.9 -194 332.7
US
Abbvie Inc
NYSE:ABBV
401B USD 6.7 170.8 16.5 23.4
US
Amgen Inc
NASDAQ:AMGN
178.8B USD 5 25.5 18.4 18.4
US
Gilead Sciences Inc
NASDAQ:GILD
150.7B USD 5.2 18.6 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.7B USD 9.9 31.5 23.1 24.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 068.4 -527.8 -574.7 -559.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
76.1B USD 5.3 16.6 15.8 17.9
AU
CSL Ltd
ASX:CSL
89.1B AUD 3.8 19.6 13.2 16.4
NL
argenx SE
XBRU:ARGX
46.9B EUR 15.2 35.6 61.7 63.4
US
Seagen Inc
F:SGT
39.3B EUR 19.9 -61.1 -65.9 -59.4
P/S Multiple
Revenue Growth P/S to Growth
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Average P/S: 3 096 549.5
24.3
44%
0.6
FR
Pharnext SCA
OTC:PNEXF
34 059 881.3
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
10%
1
US
E
Epizyme Inc
F:EPE
2 068.4
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.3
5%
1.1
AU
CSL Ltd
ASX:CSL
3.8
5%
0.8
NL
argenx SE
XBRU:ARGX
15.2
46%
0.3
US
S
Seagen Inc
F:SGT
19.9
30%
0.7
P/E Multiple
Earnings Growth PEG
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Average P/E: 45.5
Negative Multiple: -187.4 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 881.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
170.8
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.5
44%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
191%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.5
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.6
8%
2.1
AU
CSL Ltd
ASX:CSL
19.6
11%
1.8
NL
argenx SE
XBRU:ARGX
35.6
37%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.1 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Average EV/EBITDA: 23
Negative Multiple: -468.5 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 575.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.5
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.4
10%
1.8
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -574.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.8
9%
1.8
AU
CSL Ltd
ASX:CSL
13.2
8%
1.6
NL
argenx SE
XBRU:ARGX
61.7
769%
0.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -65.9 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Average EV/EBIT: 25.2
Negative Multiple: -321.6 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 332.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.4
19%
1
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
13%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.1
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
12%
1.5
AU
CSL Ltd
ASX:CSL
16.4
11%
1.5
NL
argenx SE
XBRU:ARGX
63.4
N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.4 N/A N/A

See Also

Summary
ALNY intrinsic value, competitors valuation, and company profile.
DCF Valuation
ALNY stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ALNY stock valuation using valuation multiples.
Wall Street Estimates
ALNY price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ALNY stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 301,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.